Protocol Ledger

NCT03535675 · Phase III · TERMINATED

Muscadine Plus (MPX) In Men With Prostate Cancer

Interventional Phase III clinical trial protocol NCT03535675 sponsored by Johns Hopkins University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-30 Enrollment: 59 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03535675
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)59 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03535675
Protocol FieldVerified Registry Value
NCT IdentifierNCT03535675
Consolidated Lead SponsorJohns Hopkins University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment59 participants (ACTUAL)
Registered Start Date2018-10-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johns Hopkins Medicine across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI